T501-1335 Screening compound: 3-[(4-benzyl-4H-1,2,4-triazol-3-yl)methyl]-1-[5-(1-ethyl-3,5-dimethyl-1H-pyrazol-4-yl)-1,2-oxazole-3-carbonyl]piperidine

T501-1335 Screening compound: 3-[(4-benzyl-4H-1,2,4-triazol-3-yl)methyl]-1-[5-(1-ethyl-3,5-dimethyl-1H-pyrazol-4-yl)-1,2-oxazole-3-carbonyl]piperidine
T501-1335 Screening compound: 3-[(4-benzyl-4H-1,2,4-triazol-3-yl)methyl]-1-[5-(1-ethyl-3,5-dimethyl-1H-pyrazol-4-yl)-1,2-oxazole-3-carbonyl]piperidine alternative view

Chemical Structure Depiction of ChemDiv screening compound T501-1335
3-[(4-benzyl-4H-1,2,4-triazol-3-yl)methyl]-1-[5-(1-ethyl-3,5-dimethyl-1H-pyrazol-4-yl)-1,2-oxazole-3-carbonyl]piperidine

Available from 1 mg

Formats:

  • Glass Vials (4ml Glass Vials VWR #97047-678)
  • 96-tube racks (Matrix #4247 96-well 1.4ml sealed with capmats, empty cols 1 & 12, 100uL of 10mM)

Shiptime: 1 week worldwide delivery in most cases

Compound Identifiers

ChemDiv Compound ID

T501-1335

Molecular Formula

C26H31N7O2 (C26 H31 N7 O2)

Compound Name

3-[(4-benzyl-4H-1,2,4-triazol-3-yl)methyl]-1-[5-(1-ethyl-3,5-dimethyl-1H-pyrazol-4-yl)-1,2-oxazole-3-carbonyl]piperidine

IUPAC name

3-[(4-benzyl-4H-124-triazol-3-yl)methyl]-1-[5-(1-ethyl-35-dimethyl-1H-pyrazol-4-yl)-12-oxazole-3-carbonyl]piperidine

SMILES

CCn1nc(C)c(-c2cc(C(N3CC(Cc4nncn4Cc4ccccc4)CCC3)=O)no2)c1C

InChI

InChI=1S/C26H31N7O2/c1-4-33-19(3)25(18(2)29-33)23-14-22(30-35-23)26(34)31-12-8-11-21(16-31)13-24-28-27-17-32(24)15-20-9-6-5-7-10-20/h5-7,9-10,14,17,21H,4,8,11-13,15-16H2,1-3H3/t21-/m1/s1

InChI Key

NTYMNRKCBQRRLV-OAQYLSRUSA-N

MDL Number (MFCD)

MFCD31973302

Chemical and Physical Properties

Saltdata

n/a

Molecular Weight

473.58

Hydrogen Bond Acceptors Count

7.00

Hydrogen Bond Donors Count

0.00

Rotatable Bond Count

8.00

Number of Nitrogen and Oxygen Atoms

9

Partition Coefficient, logP

2.529

Distribution Coefficient, logD

2.529

Water Solubility, LogSw

-2.74

Polar Surface Area

77.694

Acid Dissociation Constant (pKa)

19.60

Base Dissociation Constant (pKb)

3.24

Number of Chiral Centers

1.00

Percent sp3 carbon bonding

42.31

T501-1335 in Drug Discovery

Included in Screening Libraries

300k Representative Compounds Library (Bemis-Murcko Clustering Algorithm) (286253 compounds)

CNS Targets (44014 compounds)

MCL1 Targeted Library (12200 compounds)

PPI Helix Turn 3D-Mimetics Library (71298 compounds)

Protein-Protein Interaction Library (218420 compounds)

Included in 1.7M Stock Database

Therapeutical areas:
  • Nervous system
  • Digestive system
  • Respiratory tract
  • Male
  • Female
  • Hemic and lymphatic
Mechanism of action:
  • PPI modulators
  • PPI modulators
Structure:
  • Mimetics

References: we are preparing a list of scientific research reports with T501-1335 chemical compound. It will be published here after verification.

Frequently Asked Questions

How to purchase chemical compound T501-1335?
Check Price and Availability of T501-1335, then you can add required amount to the Shopping Cart. In the Shopping Cart you can again refine your selection. Once you are sure that it’s exactly what you want you can move forward with the Checkout (to pay online by credit card, or via PayPal), or Request a Quote.
What is the minimum amount of T501-1335 you sell to drug discovery company or institution?
Available from 1 mg in Glass Vials or 96-tube racks.
Delivery options for T501-1335
ChemDiv sends parcels with Express services (UPS, WC).
  • 1–2 days for small orders
  • 2–4 weeks for large selections
Delivery formats for T501-1335
  • 0.5–50 mg of dry powder sample in single glass vials, custom vials
  • DMSO solutions frozen 10μl–250μl@10mM (96 and 384 format)

Custom synthesis of T501-1335 available by request